224 related articles for article (PubMed ID: 22998452)
1. MUC1 immunotherapy is here to stay.
Kimura T; Finn OJ
Expert Opin Biol Ther; 2013 Jan; 13(1):35-49. PubMed ID: 22998452
[TBL] [Abstract][Full Text] [Related]
2. Update on Mucin-1 immunotherapy in cancer: a clinical perspective.
Rivalland G; Loveland B; Mitchell P
Expert Opin Biol Ther; 2015; 15(12):1773-87. PubMed ID: 26453294
[TBL] [Abstract][Full Text] [Related]
3. MUC1 as a target antigen for cancer immunotherapy.
Acres B; Limacher JM
Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
[TBL] [Abstract][Full Text] [Related]
4. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
5. Strategies used for MUC1 immunotherapy: human clinical studies.
Tang CK; Katsara M; Apostolopoulos V
Expert Rev Vaccines; 2008 Sep; 7(7):963-75. PubMed ID: 18767946
[TBL] [Abstract][Full Text] [Related]
6. Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
Acres B; Lacoste G; Limacher JM
Curr Top Microbiol Immunol; 2017; 405():79-97. PubMed ID: 25702159
[TBL] [Abstract][Full Text] [Related]
7. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
8. MUC1 immunotherapy.
Beatson RE; Taylor-Papadimitriou J; Burchell JM
Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
[TBL] [Abstract][Full Text] [Related]
9. Intramolecular antigenicity of MUC1, a candidate for cancer vaccines.
Wiwanitkit V
Asian Pac J Cancer Prev; 2007; 8(2):315-6. PubMed ID: 17696754
[TBL] [Abstract][Full Text] [Related]
10. MUC1-specific cytotoxic T lymphocytes in cancer therapy: induction and challenge.
Roulois D; Grégoire M; Fonteneau JF
Biomed Res Int; 2013; 2013():871936. PubMed ID: 23509794
[TBL] [Abstract][Full Text] [Related]
11. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
[TBL] [Abstract][Full Text] [Related]
12. Role of transmembrane glycoprotein mucin 1 (MUC1) in various types of colorectal cancer and therapies: Current research status and updates.
Guo M; You C; Dou J
Biomed Pharmacother; 2018 Nov; 107():1318-1325. PubMed ID: 30257347
[TBL] [Abstract][Full Text] [Related]
13. Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice.
Yuan S; Shi C; Ling R; Wang T; Wang H; Han W
J Cancer Res Clin Oncol; 2010 Sep; 136(9):1359-67. PubMed ID: 20127358
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.
Beckwith DM; Cudic M
Semin Immunol; 2020 Feb; 47():101389. PubMed ID: 31926647
[TBL] [Abstract][Full Text] [Related]
16. The surface dominant antigen MUC1 is required for colorectal cancer stem cell vaccine to exert anti-tumor efficacy.
Guo M; You C; Dong W; Luo B; Wu Y; Chen Y; Li J; Pan M; Li M; Zhao F; Dou J
Biomed Pharmacother; 2020 Dec; 132():110804. PubMed ID: 33017767
[TBL] [Abstract][Full Text] [Related]
17. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
18. Emepepimut-S for non-small cell lung cancer.
Corrales-Rodriguez L; Blais N; Soulières D
Expert Opin Biol Ther; 2011 Aug; 11(8):1091-7. PubMed ID: 21689064
[TBL] [Abstract][Full Text] [Related]
19. A review on development of MUC1-based cancer vaccine.
Gao T; Cen Q; Lei H
Biomed Pharmacother; 2020 Dec; 132():110888. PubMed ID: 33113416
[TBL] [Abstract][Full Text] [Related]
20. [Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL].
Masaki Y; Oka M
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1679-80. PubMed ID: 8886044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
